Silver Book Fact

Development of a neuroprotective drug could potentially reduce disability from stroke by 50%.

Goldman, Dana P., Baoping Shang, Jayanta Bhattacharya, Alan M. Garber, Michael Hurd, Geoffrey F. Joyce, Darius N. Lakdawalla, Constantijn Panis, and Paul G. Shekelle. Consequences of Health Trends and Medical Innovation for the Future Elderly: Health and costs of the future elderly. Health Affairs Web Exclusive Collection. 2005; 24(2). http://content.healthaffairs.org/cgi/content/abstract/hlthaff.w5.r5v1

Reference

Title
Consequences of Health Trends and Medical Innovation for the Future Elderly: Health and costs of the future elderly
Publication
Health Affairs Web Exclusive Collection
Publication Date
2005
Authors
Goldman, Dana P., Baoping Shang, Jayanta Bhattacharya, Alan M. Garber, Michael Hurd, Geoffrey F. Joyce, Darius N. Lakdawalla, Constantijn Panis, and Paul G. Shekelle
Volume & Issue
Volume 24, Issue 2
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Improvements in QoL from TAVR in SAS patients
    Symptomatic aortic stenosis (SAS) patients who underwent transcatheter aortic valve replacement (TAVR) experienced quality of life (QoL) improvements from 5.3 at baseline (10 point scale with 10=best imaginable health state)…  
  • Cardiovascular disease mortality has declined by over 50% since 1950, contributing more than any other factor to the increase of life expectancy during the past few decades.  
  • Direct thrombin inhibitor reduced relative risk of venous thromboembolism
    An investigational direct thrombin inhibitor reduced relative risk of venous thromboembolism after total hip replacement surgery by 65.7%—compared to a currently available treatment.  
  • Cost-savings associated with Warfarin use in AFib patients
    Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.  
  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…